^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Title:

Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma

Published date:
02/08/2021
Excerpt:
The patient was diagnosed with lung adenocarcinoma...biopsy tissue sample revealed a CD74–ROS1 gene fusion...patient started the first-line therapy with ceritinib (450 mg orally once a day). Two months later, he achieved a partial response...However, the disease progressed at the end of July as PET-CT revealed multiple lymph nodes metastases and bone destruction...A second NGS assay found a possible resistance mutation of c.6012T>G (p.F2004L) (MAF 1.65%) in ROS1 kinase domain in the plasma circulating tumor DNA in addition to the ROS1 fusion.
DOI:
10.1136/jitc-2020-001967